ESLA vs. SABS, DYAI, CYTH, NKGN, SRZN, INKT, TARA, OKYO, INAB, and CRTX
Should you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include SAB Biotherapeutics (SABS), Dyadic International (DYAI), Cyclo Therapeutics (CYTH), NKGen Biotech (NKGN), Surrozen (SRZN), MiNK Therapeutics (INKT), Protara Therapeutics (TARA), OKYO Pharma (OKYO), IN8bio (INAB), and Cortexyme (CRTX). These companies are all part of the "medical" sector.
SAB Biotherapeutics (NASDAQ:SABS) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, community ranking, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.
7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 26.0% of SAB Biotherapeutics shares are held by company insiders. Comparatively, 55.1% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
SAB Biotherapeutics currently has a consensus target price of $15.50, indicating a potential upside of 267.30%. Given Estrella Immunopharma's higher probable upside, research analysts clearly believe SAB Biotherapeutics is more favorable than Estrella Immunopharma.
In the previous week, SAB Biotherapeutics had 2 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 0 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.34 beat SAB Biotherapeutics' score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the media.
Estrella Immunopharma has a net margin of 0.00% compared to Estrella Immunopharma's net margin of -1,884.10%. SAB Biotherapeutics' return on equity of -23.59% beat Estrella Immunopharma's return on equity.
Estrella Immunopharma has lower revenue, but higher earnings than SAB Biotherapeutics.
SAB Biotherapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.
SAB Biotherapeutics received 17 more outperform votes than Estrella Immunopharma when rated by MarketBeat users.
Summary
SAB Biotherapeutics beats Estrella Immunopharma on 8 of the 13 factors compared between the two stocks.
Get Estrella Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Estrella Immunopharma Competitors List
Related Companies and Tools
